Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/PO.22.00536 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Complex dyslipidemia induced by Lorlatinib therapy: A case study.
J Clin Lipidol
October 2024
Section of Nutrition and Metabolic Diseases, Division of Endocrinology, Department of Internal Medicine and the Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address:
Context: Lorlatinib is an anaplastic lymphoma kinase (ALK) inhibitor, which is currently used for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC). Previous reports have noticed an association between lorlatinib and hyperlipidemia, however the specific mechanisms for this side effect remain unknown. Some investigators have reported nephrotic syndrome to be the underlying cause of lorlatinib-induced hyperlipidemia.
View Article and Find Full Text PDFLorlatinib overcomes alectinib-induced hemolytic anemia in an ALK fusion positive non-small-cell lung cancer patient with severe tumor-associated liver failure: A case report.
Thorac Cancer
December 2024
Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Hemolytic anemia is a rare and unique complication of alectinib, not observed with other anaplastic lymphoma kinase (ALK) inhibitors. Here, we present a case of an ALK fusion-positive non-small-cell lung cancer (NSCLC) patient who developed liver failure due to diffuse liver metastasis at initial diagnosis. Treatment was initiated with low-dose alectinib, but the patient developed severe hemolytic anemia.
View Article and Find Full Text PDFIn-depth theoretical modeling to explore the mechanism of TPX-0131 overcoming lorlatinib resistance to ALK mutation.
Comput Biol Med
December 2024
Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, Zhejiang, PR China. Electronic address:
A number of anaplastic lymphoma kinase (ALK) inhibitors have been clinically approved, with lorlatinib, particularly as a third-generation drug, demonstrating efficacy against various drug-resistant ALK single mutations. However, continued clinical use of lorlatinib has led to the emergence of ALK double mutations conferring resistance to lorlatinib, notably ALK. TPX-0131 is a potential fourth-generation ALK inhibitor currently under development.
View Article and Find Full Text PDFEarly Prediction and Impact Assessment of CYP3A4-Related Drug-Drug Interactions for Small-Molecule Anticancer Drugs Using Human-CYP3A4-Transgenic Mouse Models.
Drug Metab Dispos
October 2024
Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (D.D., J.H.B., A.D.R.H., T.P.C.D.); Utrecht Institute of Pharmaceutical Sciences (J.H.B.) and Department of Clinical Pharmacy, University Medical Center Utrecht (A.D.R.H.), Utrecht University, Utrecht, The Netherlands; Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands (A.D.R.H.); and Department of Pharmacy, Uppsala University, Uppsala, Sweden (T.P.C.D.).
Early detection of drug-drug interactions (DDIs) can facilitate timely drug development decisions, prevent unnecessary restrictions on patient enrollment, resulting in clinical study populations that are not representative of the indicated study population, and allow for appropriate dose adjustments to ensure safety in clinical trials. All of these factors contribute to a streamlined drug approval process and enhanced patient safety. Here we describe a new approach for early prediction of the magnitude of change in exposure for cytochrome P450 (P450) CYP3A4-related DDIs of small-molecule anticancer drugs based on the model-based extrapolation of human-CYP3A4-transgenic mice pharmacokinetics to humans.
View Article and Find Full Text PDFCorrelation between ALK+ non-small cell lung cancer targeted therapy and thrombosis: a systematic review and network meta-analysis.
BMJ Open
September 2024
Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Article Synopsis
- The study looked at different treatments for lung cancer to see which ones cause fewer blood clots.* -
- It included lots of data from medical research and compared therapies like chemotherapy and ALK inhibitors.* -
- The results showed that chemotherapy and some other drugs had a lower chance of causing blood clots than one specific drug called crizotinib.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!